PPARD rs2016520 (T/C) and NOS1AP rs12742393 (A/C) polymorphisms affect therapeutic efficacy of nateglinide in Chinese patients with type 2 diabetes mellitus

Abstract Background Genetic polymorphisms in the PPARD and NOS1AP is associated with type 2 diabetes mellitus (T2DM); however, there is no evidence about its impact on the therapeutic efficacy of nateglinide. This study was designed to investigate a potential association of PPARD rs2016520 (T/C) and...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tao Wang, Jin-Fang Song, Xue-Yan Zhou, Cheng-Lin Li, Xiao-Xing Yin, Qian Lu
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	PPARD NOS1AP Genetic polymorphism Type 2 diabetes mellitus Nateglinide Internal medicine RC31-1245 Genetics QH426-470
Acceso en línea:	https://doaj.org/article/f92d501db35445b38ef50844de64aaab
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f92d501db35445b38ef50844de64aaab
record_format	dspace
spelling	oai:doaj.org-article:f92d501db35445b38ef50844de64aaab2021-11-14T12:07:43ZPPARD rs2016520 (T/C) and NOS1AP rs12742393 (A/C) polymorphisms affect therapeutic efficacy of nateglinide in Chinese patients with type 2 diabetes mellitus10.1186/s12920-021-01108-51755-8794https://doaj.org/article/f92d501db35445b38ef50844de64aaab2021-11-01T00:00:00Zhttps://doi.org/10.1186/s12920-021-01108-5https://doaj.org/toc/1755-8794Abstract Background Genetic polymorphisms in the PPARD and NOS1AP is associated with type 2 diabetes mellitus (T2DM); however, there is no evidence about its impact on the therapeutic efficacy of nateglinide. This study was designed to investigate a potential association of PPARD rs2016520 (T/C) and NOS1AP rs12742393 (A/C) polymorphisms with efficacy of nateglinide in newly diagnosed Chinese patients with type 2 diabetes mellitus (T2DM). Methods Sixty patients with newly diagnosed T2DM were enrolled to identify PPARD rs2016520 and NOS1AP rs12742393 genotypes using the polymerase chain reaction-restriction fragment length polymorphism assay (PCR–RFLP). All subjects were treated with nateglinide (360 mg/day) for 8 weeks. Anthropometric measurements, clinical laboratory tests were obtained at baseline and after 8 weeks of nateglinide treatment. Results After nateglinide treatment for 8 consecutive weeks, patients with at least one C allele of PPARD rs2016520 showed a smaller decrease in post plasma glucose (PPG), homeostasis model assessment for beta cell function (HOMA-B) than those with the TT genotype did (P < 0.05). In patients with the AA genotype of NOS1AP rs12742393, the drug showed better efficacy with respect to levels of fasting plasma glucose (FPG), fasting serum insulin (FINS), HOMA-B and homeostasis model assessment for insulin resistance (HOMA-IR) than in patients with the AC + CC genotype (P < 0.05). NOS1AP rs12742393 genotype distribution and allele frequency were associated with responsiveness of nateglinide treatment (P < 0.05). Conclusions The PPARD rs2016520 and NOS1AP rs12742393 polymorphisms were associated with nateglinide monotherapy efficacy in Chinese patients with newly diagnosed T2DM. Trial registration Chinese Clinical Trial Register ChiCTR13003536, date of registration: May 14, 2013.Tao WangJin-Fang SongXue-Yan ZhouCheng-Lin LiXiao-Xing YinQian LuBMCarticlePPARDNOS1APGenetic polymorphismType 2 diabetes mellitusNateglinideInternal medicineRC31-1245GeneticsQH426-470ENBMC Medical Genomics, Vol 14, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	PPARD NOS1AP Genetic polymorphism Type 2 diabetes mellitus Nateglinide Internal medicine RC31-1245 Genetics QH426-470
spellingShingle	PPARD NOS1AP Genetic polymorphism Type 2 diabetes mellitus Nateglinide Internal medicine RC31-1245 Genetics QH426-470 Tao Wang Jin-Fang Song Xue-Yan Zhou Cheng-Lin Li Xiao-Xing Yin Qian Lu PPARD rs2016520 (T/C) and NOS1AP rs12742393 (A/C) polymorphisms affect therapeutic efficacy of nateglinide in Chinese patients with type 2 diabetes mellitus
description	Abstract Background Genetic polymorphisms in the PPARD and NOS1AP is associated with type 2 diabetes mellitus (T2DM); however, there is no evidence about its impact on the therapeutic efficacy of nateglinide. This study was designed to investigate a potential association of PPARD rs2016520 (T/C) and NOS1AP rs12742393 (A/C) polymorphisms with efficacy of nateglinide in newly diagnosed Chinese patients with type 2 diabetes mellitus (T2DM). Methods Sixty patients with newly diagnosed T2DM were enrolled to identify PPARD rs2016520 and NOS1AP rs12742393 genotypes using the polymerase chain reaction-restriction fragment length polymorphism assay (PCR–RFLP). All subjects were treated with nateglinide (360 mg/day) for 8 weeks. Anthropometric measurements, clinical laboratory tests were obtained at baseline and after 8 weeks of nateglinide treatment. Results After nateglinide treatment for 8 consecutive weeks, patients with at least one C allele of PPARD rs2016520 showed a smaller decrease in post plasma glucose (PPG), homeostasis model assessment for beta cell function (HOMA-B) than those with the TT genotype did (P < 0.05). In patients with the AA genotype of NOS1AP rs12742393, the drug showed better efficacy with respect to levels of fasting plasma glucose (FPG), fasting serum insulin (FINS), HOMA-B and homeostasis model assessment for insulin resistance (HOMA-IR) than in patients with the AC + CC genotype (P < 0.05). NOS1AP rs12742393 genotype distribution and allele frequency were associated with responsiveness of nateglinide treatment (P < 0.05). Conclusions The PPARD rs2016520 and NOS1AP rs12742393 polymorphisms were associated with nateglinide monotherapy efficacy in Chinese patients with newly diagnosed T2DM. Trial registration Chinese Clinical Trial Register ChiCTR13003536, date of registration: May 14, 2013.
format	article
author	Tao Wang Jin-Fang Song Xue-Yan Zhou Cheng-Lin Li Xiao-Xing Yin Qian Lu
author_facet	Tao Wang Jin-Fang Song Xue-Yan Zhou Cheng-Lin Li Xiao-Xing Yin Qian Lu
author_sort	Tao Wang
title	PPARD rs2016520 (T/C) and NOS1AP rs12742393 (A/C) polymorphisms affect therapeutic efficacy of nateglinide in Chinese patients with type 2 diabetes mellitus
title_short	PPARD rs2016520 (T/C) and NOS1AP rs12742393 (A/C) polymorphisms affect therapeutic efficacy of nateglinide in Chinese patients with type 2 diabetes mellitus
title_full	PPARD rs2016520 (T/C) and NOS1AP rs12742393 (A/C) polymorphisms affect therapeutic efficacy of nateglinide in Chinese patients with type 2 diabetes mellitus
title_fullStr	PPARD rs2016520 (T/C) and NOS1AP rs12742393 (A/C) polymorphisms affect therapeutic efficacy of nateglinide in Chinese patients with type 2 diabetes mellitus
title_full_unstemmed	PPARD rs2016520 (T/C) and NOS1AP rs12742393 (A/C) polymorphisms affect therapeutic efficacy of nateglinide in Chinese patients with type 2 diabetes mellitus
title_sort	ppard rs2016520 (t/c) and nos1ap rs12742393 (a/c) polymorphisms affect therapeutic efficacy of nateglinide in chinese patients with type 2 diabetes mellitus
publisher	BMC
publishDate	2021
url	https://doaj.org/article/f92d501db35445b38ef50844de64aaab
work_keys_str_mv	AT taowang ppardrs2016520tcandnos1aprs12742393acpolymorphismsaffecttherapeuticefficacyofnateglinideinchinesepatientswithtype2diabetesmellitus AT jinfangsong ppardrs2016520tcandnos1aprs12742393acpolymorphismsaffecttherapeuticefficacyofnateglinideinchinesepatientswithtype2diabetesmellitus AT xueyanzhou ppardrs2016520tcandnos1aprs12742393acpolymorphismsaffecttherapeuticefficacyofnateglinideinchinesepatientswithtype2diabetesmellitus AT chenglinli ppardrs2016520tcandnos1aprs12742393acpolymorphismsaffecttherapeuticefficacyofnateglinideinchinesepatientswithtype2diabetesmellitus AT xiaoxingyin ppardrs2016520tcandnos1aprs12742393acpolymorphismsaffecttherapeuticefficacyofnateglinideinchinesepatientswithtype2diabetesmellitus AT qianlu ppardrs2016520tcandnos1aprs12742393acpolymorphismsaffecttherapeuticefficacyofnateglinideinchinesepatientswithtype2diabetesmellitus
_version_	1718429443210346496

PPARD rs2016520 (T/C) and NOS1AP rs12742393 (A/C) polymorphisms affect therapeutic efficacy of nateglinide in Chinese patients with type 2 diabetes mellitus

Ejemplares similares